Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

The new lower prices apply to some doses of Zepbound provided in vials but not the autoinjector pens.

Higher volumes of drugs like Mounjaro, Zepbound, Verzenio, Jardiance and Taltz were partially offset by lower sales of Trulicity. Lilly’s new products also contributed to sales growth.

Whales with a lot of money to spend have taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli ...

Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter results were rather uneventful, with the company already announcing ...

Sales of Lilly’s incretin medicines, Mounjaro, Trulicity and Zepbound, missed estimates, while that of non-incretin drugs like Jardiance, Taltz and Verzenio beat expectations. Lilly’s non ...

2 Lilly defines Growth Products as select products launched prior to 2022, which currently consist of Cyramza, Emgality, Jardiance, Olumiant, Retevmo, Taltz, Trulicity, Tyvyt and Verzenio.